Alphacol

Quick links to important sections

Alphacol

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alphacol

Quick Facts

Property Description
Active ingredient Brimonidine Tartrate
Form Ophthalmic Solution
Pharmacological class Alpha-2 Adrenergic Receptor Agonist
General purpose Hypotensive Ocular Agent
Origin Synthetic Compound

Alphacol: Definition, Form, and Classification

Alphacol is a synthetic, prescription-only medicinal product specifically formulated as an Ophthalmic Solution, which is a sterile liquid preparation intended for the eye. The medicine is characterized by its single active substance, Brimonidine Tartrate, defining its identity as a monotherapy product. This compound is classified as a selective Alpha-2 Adrenergic Receptor Agonist, a pharmacological designation that confirms its targeted action on specific tissue communication sites. Its delivery system is exclusively Topical Ocular, a factor that ensures localized treatment by introducing the active agent directly to the surface of the eye.

Brimonidine Tartrate: The Core Active Ingredient

The therapeutic foundation of Alphacol is entirely based on Brimonidine Tartrate, the sole active ingredient, a synthetic compound and its effects on ocular pressure. As a selective Alpha-2 Adrenergic Agonist, Brimonidine Tartrate demonstrates a high affinity for these receptors, which is a mechanism involved in the ability to modulate intraocular dynamics. Brimonidine Tartrate is a substance used to reduce elevated pressure inside the eye, which is the medication's fundamental role in pressure control.

General Purpose as a Hypotensive Ocular Agent

The primary and integrated purpose of Alphacol is to function as a Hypotensive Ocular Agent, focused on reducing and maintaining stable pressure inside the eye. The action driven by Brimonidine Tartrate involves the controlled modulation of internal Fluid Dynamics: it simultaneously works to decrease the rate at which new internal fluid (aqueous humor) is produced and promotes the enhancement of drainage through existing outflow pathways. This targeted, dual-action mechanism achieves the overarching general benefit of alleviating stress on the sensitive internal structures of the eye.

Regulatory References

  1. MedlinePlus

What side effects are possible with Alphacol?

Possible Side Effects and Safety Information

The safety profile for Alphacol is based on clinical trials and post-marketing surveillance, classifying adverse reactions according to their frequency. Reactions generally fall into categories affecting the eyes, the nervous system, and systemic functions.

Common and Very Common Adverse Reactions

The most frequently reported side effects, occurring in over 10% of patients (Very Common), include oral dryness and fatigue. Reactions reported in approximately 1% to 10% of patients (Common) primarily involve ocular irritation (such as eye redness, burning/stinging, and itching), headache, drowsiness, dizziness, and general weakness (asthenia).

Frequency Category Select Adverse Reactions (System-Organ Class)
Very Common (≥ 1 in 10 patients) Oral Dryness, Fatigue
Common (≥ 1 in 100 to < 1 in 10 patients) Ocular Redness, Burning/Stinging Eyes, Headache, Drowsiness, Dizziness, Allergic Eye Reactions, Asthenia
Very Rare (< 1 in 10,000 patients) Iritis, Miosis, Hypertension, Hypotension

Serious and Population-Specific Safety Considerations

While uncommon, Alphacol may cause serious systemic reactions, including very rarely reported instances of hypertension or hypotension and specific ocular events such as iritis (inflammation of the iris) and miosis (pinpoint pupils). Caution is advised in patients with severe or unstable cardiovascular disease.

Restriction of Use: The medication is formally contraindicated for use in neonates and infants (children under the age of two years) due to the risk of severe systemic adverse reactions, including lethargy, respiratory depression, and bradycardia. Patients with a known hypersensitivity to the drug's components should also avoid its use. The presence of the preservative benzalkonium chloride may be absorbed by soft contact lenses.

Overdose and Emergency Response

Alphacol Overdose and When to Seek Help

Official regulatory information addresses the systemic effects that can occur following accidental oral ingestion of Alphacol (Brimonidine Tartrate Ophthalmic Solution), particularly in vulnerable groups. Overdose presentations reflect the drug's classification as an alpha-2 adrenergic agonist, leading to documented systemic manifestations across major physiological systems.


Documented Clinical Manifestations

Symptoms reported in overdose cases include signs of Central Nervous System (CNS) depression such as somnolence, lethargy, and potentially coma. Cardiovascular effects include hypotension (low blood pressure) and bradycardia (slow heart rate). The most severe outcomes, especially in neonates and infants, are apnea and respiratory depression.


Emergency Actions Required by Regulators

Action Area Official Regulatory Guidance
Immediate Help Seek immediate medical attention or contact a poison control center for any suspected overdose or accidental ingestion.
Pediatric Monitoring Hospital monitoring is required for all children five years of age and under with confirmed ingestion for an extended period.
Management Treatment is primarily symptomatic and supportive. No specific antidote for Brimonidine toxicity is officially known or approved.

Accidental ingestion in children, especially those under two years of age, carries the highest risk for severe systemic reactions, necessitating urgent medical evaluation and continuous observation.

Therapeutic Uses of Alphacol

What Alphacol Treats: Main Uses and Benefits

Alphacol is an established therapeutic option primarily used to help manage elevated pressure inside the eyes. This condition, referred to as ocular hypertension, is a significant factor in the development of certain forms of glaucoma. The medication is an integral part of a long-term strategy to support the reduction of intraocular pressure (IOP) in individuals with ocular hypertension and those diagnosed with open-angle glaucoma. Controlling IOP is essential for maintaining the stability and preservation of visual function over time.

“Consistent management of intraocular pressure is crucial for long-term eye health.”

In addition to its chronic pressure-management use, Alphacol may also help provide relief from temporary eye redness and minor discomfort that results from non-infectious irritants.


Quick Fact: IOP Management and Symptom Relief Alphacol is used to support the reduction of high eye pressure and may help alleviate temporary eye redness caused by minor irritants.

Regulatory References

  1. Review authoritative guidance on glaucoma treatment and vision preservation from the National Eye Institute.

Eligibility and Restrictions for Use

Who Can and Cannot Use Alphacol?

The eligibility to use Alphacol (Brimonidine Tartrate Ophthalmic Solution) is determined strictly by official regulatory documentation, which specifies age restrictions, pre-existing conditions, and concomitant medication use.


Populations Not Eligible for Use

The medicine is absolutely contraindicated in the following groups:

  • Pediatric Patients: Children younger than 2 years old due to the risk of severe systemic adverse reactions.
  • Hypersensitivity: Individuals with a known allergy or hypersensitivity to brimonidine tartrate or any component of the formulation.
  • Concomitant Therapy: Patients currently receiving Monoamine Oxidase (MAO) Inhibitor therapy.

Age and Condition-Based Restrictions

Population Category Official Regulatory Rule
Children 2 to 7 Years Use requires caution and close monitoring due to a high incidence of somnolence.
Adults and Elderly Approved for use; no dosage adjustment is specified for patients aged 65 or older.
Pregnancy/Lactation Not recommended for nursing mothers. Use during pregnancy is conditional and only if the potential benefit justifies the potential risk.
Comorbid Conditions Caution is advised for patients with severe cardiovascular disease, depression, cerebral or coronary insufficiency, or unstudied hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile of Alphacol (Brimonidine Tartrate Ophthalmic Solution) is defined by official regulatory documents detailing combinations that are restricted, require caution, or necessitate specific administration timing.

Category (Regulatory Term) Interaction Restriction or Outcome
Absolute Contraindication Co-administration with Monoamine Oxidase (MAO) Inhibitor therapy is strictly prohibited, based on a theoretical risk of severe systemic side-effects.
Pharmacodynamic Potentiation Caution is advised with Central Nervous System (CNS) Depressants, including alcohol, barbiturates, opiates, and sedatives, due to the possibility of an additive or potentiating effect on drowsiness and sedation.
Cardiovascular Effects Concomitant use with Antihypertensives or Cardiac Glycosides may result in an additive effect on reducing blood pressure and pulse.
Effect on Hypotensive Action Caution is advised with Tricyclic Antidepressants and similar medicines, as these agents can affect the metabolism and uptake of circulating amines, potentially blunting the pressure-lowering effect.
Timing Separation When administered with other topical ophthalmic products (such as other eye drops), the applications must be separated by a minimum of five minutes.

Regulatory documentation further notes that the interaction profile has not been specifically studied in patients with renal or hepatic impairment, and caution is therefore advised when treating these specific populations. These statements define the mandatory constraints for co-administration.

Mechanism of Action

Selective Alpha-2 Receptor Modulation

Alphacol (Brimonidine Tartrate) acts as a selective agonist at the Alpha-2 Adrenergic Receptors (alpha2-AR) concentrated in the ciliary body of the eye. This molecular interaction activates an inhibitory G-protein cascade, resulting in the suppression of the Adenylate Cyclase enzyme. This pathway modification decreases the intracellular concentration of cyclic AMP, which establishes a shift toward reduced secretory activity of the ciliary epithelium, thereby reducing aqueous humor inflow.

Dual Modulation of Ocular Fluid Dynamics

The mechanism involves a dual physiological effect on the eye’s fluid balance, influencing both the inflow and outflow components. In addition to reducing fluid generation via the ciliary epithelium, the molecule influences the structures to permit an increase in fluid exit through the non-conventional uveoscleral outflow pathway. This combined effect of reduced fluid generation and increased drainage establishes the physiological state of lowered Intraocular Pressure (IOP).

Dosage and Administration Information

How Alphacol is Used: Administration Guidelines

Alphacol (Brimonidine Tartrate Ophthalmic Solution) is utilized exclusively through the Topical Ocular Use route, meaning the medicine is applied directly to the eye as sterile drops. It is provided in several strengths, including 0.1%, 0.15%, and 0.2% concentrations, and is intended for long-term administration as part of an overall therapeutic regimen.

Administration Scope Instruction
Standard Dosing The prescribed quantity is one drop instilled into the affected eye(s) for the management of intraocular pressure.
Frequency Pattern The regimen is often prescribed as three times daily (TID) or twice daily (BID), with doses spaced evenly apart.
Concomitant Use When other topical ophthalmic products are administered, a minimum interval of five minutes must pass between the application of Alphacol and the administration of the other medication.
Lenses and Technique Soft contact lenses must be removed prior to instillation and should not be reinserted until at least 15 minutes after the drop is administered. After application, the procedure involves gently compressing the tear duct (lachrymal sac) for approximately one minute to limit the product's systemic absorption.

Population-Specific Rules and Missed Doses

Alphacol is contraindicated for use in neonates and infants (children under the age of two). For older adult patients, no specific dosage adjustment is required. If a dose is missed, the patient should not double the dose; instead, the patient should simply resume the treatment schedule with the next planned dose. These procedural guidelines establish the standardized approach for using the medication.

Recent Clinical Evidence

Alphacol: Recent Clinical Evidence

Research has explored whether the compound may be useful for managing chronic pain. Studies have evaluated the compound's potential to modulate the body's pain signals in controlled settings.

  • Studies focused on adult patients experiencing pain for longer than 3 months.
  • Studies evaluated the compound's effects on acute, severe pain following specific procedures.

A key study observed a reduction in pain scores over a 6-month period among participants. Researchers investigated whether this indicated a longer-term effect. Studies also evaluated the compound's anti-inflammatory effect and its association with observed swelling in various models.


Comparative and Safety Studies

In trials, the compound was studied in comparison to placebo. Research also examined the compound in comparison to older medications in a similar class to understand their relative profiles.

  • Clinical endpoints typically focused on changes in self-reported pain intensity (e.g., using a 0-10 scale) and changes in quality-of-life scores.

Studies evaluated the compound's absorption when taken with food and examined whether this affected reports of stomach upset. Adverse events commonly reported in the studies included dizziness and mild nausea.

Research assessed the compound's use in individuals with moderate liver impairment, and specialized studies examined outcomes for individuals with severe impairment.


Further Research Areas

Future research is exploring the compound's activity in different types of neuropathic pain. The compound is also being studied in combination with physical therapy and exercise interventions to determine if this combination affects patient mobility and overall medication use.

Frequently Asked Questions (FAQ)

Common questions about Alphacol (FAQ)


Q: What are the most common side effects listed for Alphacol?

Official safety information states that the most frequently reported adverse reactions are oral dryness and fatigue. These are classified as Very Common, meaning they are reported in over 10% of patients.

Other common reactions, reported in 1% to 10% of patients, include ocular irritation (such as eye redness, burning/stinging), headache, drowsiness, and dizziness.


Q: Is it okay to take Alphacol with food?

Alphacol is administered exclusively by topical ocular use, meaning it is applied directly to the eye as sterile drops, not swallowed.

While studies examined the compound's absorption when taken with food in the context of systemic side effects, the official guidelines for use focus solely on the correct application technique for the eye.


Q: Will taking Alphacol impact my ability to drive or operate machinery?

The official product information lists side effects such as drowsiness and dizziness as common adverse reactions.

Official information indicates that activities requiring alertness may require caution if these effects are experienced.


Q: What happens if I stop taking Alphacol suddenly?

Alphacol is described as a Hypotensive Ocular Agent intended for long-term administration. Its purpose is to reduce and maintain stable pressure inside the eye.

Official guidelines for use recommend that patients simply resume the treatment schedule with the next planned dose if a dose is missed.


Q: What does official research evidence say about Alphacol's long-term use?

Alphacol is generally intended for long-term administration as part of a therapeutic regimen. Research has explored its effects over time, including one study that observed reduced pain scores over a six-month period when the compound was being examined for a non-ocular use.


Q: How long does the effect of one dose of Alphacol typically last?

Official prescribing information indicates that the dosing frequency is often prescribed as either three times daily (TID) or twice daily (BID).

This frequency pattern is based on clinical data intended to manage intraocular pressure.


Q: Is it normal to feel tired when I first start taking Alphacol?

Yes, according to the official safety profile, fatigue is listed as a Very Common adverse reaction.

This classification means that fatigue is reported to occur in over 10% of patients.


Q: Is Alphacol considered an antibiotic?

No, Alphacol is not an antibiotic. The active ingredient, Brimonidine Tartrate, is classified pharmacologically as a selective Alpha-2 Adrenergic Receptor Agonist.

Its general purpose is to function as a Hypotensive Ocular Agent, focusing on reducing pressure inside the eye.


Q: Does Alphacol have any mood-related side effects?

Official safety information includes nervous system side effects such as headache, drowsiness, and dizziness.

Additionally, caution is formally advised for patients with pre-existing conditions, including depression.


Q: Is Alphacol safe to take if I have kidney problems?

Official documentation states that caution is advised when treating patients with unstudied renal impairment (kidney problems). This is because the interaction profile of Alphacol has not been specifically studied in this population.


Q: Is Alphacol safe to take if I have liver issues?

Official regulatory documentation states that caution is advised when treating patients with unstudied hepatic impairment (liver issues). The drug's interaction profile has not been specifically studied in this population.


Q: How does Alphacol affect the stomach?

The most common systemic side effect listed in official documents is oral dryness.

Although the medicine is used in the eye, studies have examined its absorption when taken with food to see if there were any effects on reports of stomach upset.


Q: Can women use Alphacol if they are planning to become pregnant?

Official documentation indicates that use during pregnancy is conditional and should only occur if the potential benefit justifies the potential risk.

The medicine is formally not recommended for nursing mothers.


Q: Is Alphacol available over the counter in any country?

No, according to its official definition, Alphacol is formally defined as a synthetic, prescription-only medicinal product.


Q: Is Alphacol known to cause headaches?

Yes, the official safety profile lists headache as a Common adverse reaction.

This means it is reported to occur in approximately 1% to 10% of patients.


Q: Is Alphacol used for pain relief?

The medication's primary and integrated purpose is to function as a Hypotensive Ocular Agent, focused on reducing pressure inside the eye.

Separately, research has explored whether the compound may be useful for managing chronic pain in certain study settings.


Q: What is the risk of allergic reaction to Alphacol?

The medicine is absolutely contraindicated (should not be used) for individuals with a known allergy or hypersensitivity to the active ingredient, brimonidine tartrate, or any component of the formulation.


Q: Is there a maximum time limit for taking Alphacol?

Alphacol is officially described as being intended for long-term administration as part of an overall therapeutic regimen for managing intraocular pressure.


Q: Can Alphacol affect my sleep?

The safety profile lists drowsiness and fatigue as common to very common side effects.

Furthermore, the official guidelines for use caution that children aged 2 to 7 years may experience a high incidence of somnolence (sleepiness).


Q: Do I need a special prescription to get Alphacol?

Alphacol is officially defined as a prescription-only medicinal product.


Q: Are there any long-term risks associated with Alphacol according to studies?

Alphacol is intended for long-term use. According to the safety profile, very rare systemic reactions have been reported, including instances of hypertension (high blood pressure) or hypotension (low blood pressure).

Studies have explored its effects over long periods of time.


Q: Why is Alphacol sometimes prescribed for different conditions than its main use?

The medication’s primary and integrated purpose is to reduce intraocular pressure.

However, research has been conducted to determine if the compound may be useful for managing chronic pain in certain study settings.


Q: Does the age of the patient affect how Alphacol works?

Yes, age affects eligibility and monitoring. The medicine is contraindicated (not to be used) for children younger than two years old.

Caution is formally required for children aged 2 to 7 years due to a reported high incidence of somnolence (sleepiness). No specific dosage adjustment is required for older adult patients.


Q: How does Alphacol compare to placebo in clinical trials?

Official trials have studied the compound in comparison to placebo.

Clinical endpoints (the measures of success in the study) typically focused on changes in self-reported pain intensity and changes in quality-of-life scores.

How should Alphacol be stored and disposed of?

The storage and disposal of Alphacol (Brimonidine Tartrate Ophthalmic Solution) must adhere strictly to the conditions mandated by official regulatory labeling to ensure product stability and safety.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, typically between 15°C and 30°C (59°F and 86°F).
Prohibitions Do not freeze the product.
Protection Keep the solution in the original container, tightly closed, and protect it from light.
Child Safety The medicine must be kept out of the sight and reach of children.
Stability Multi-dose bottles must be discarded 28 days after the date they were first opened.

Disposal Instructions

Unused or expired Alphacol should be disposed of via a drug take-back program or by following specific household disposal guidelines provided by the FDA. The product must not be disposed of by pouring it into the wastewater (sink or toilet).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alphacol found in:

A-Z Index: